论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Gildea TR, DaCosta Byfield S, Hogarth DK, Wilson DS, Quinn CC
Received 12 January 2017
Accepted for publication 7 April 2017
Published 12 May 2017 Volume 2017:9 Pages 261—269
DOI https://doi.org/10.2147/CEOR.S132259
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Lucy Goodman
Peer reviewer comments 2
Editor who approved publication: Dr Giorgio Lorenzo Colombo
Purpose: Diagnosis of lung cancer at advanced stages can result in missed
treatment opportunities, worse outcomes, and higher health care costs. This
study evaluated the wait time to diagnose non-small-cell lung cancer (NSCLC)
and the cost of diagnosis and treatment based on the stage at diagnosis.
Patients and
methods: Adult patients diagnosed with NSCLC between January 2007 and September
2011 were identified from a proprietary oncology registry and linked to health
insurance claims from a large US health insurance company. Continuous
enrollment in the health plan was required for at least 12 months
prediagnosis (baseline) and at least 3 months postdiagnosis (follow-up).
Use of diagnostic tests and time to diagnosis were examined. The rates of
health care utilization and per-patient per-month (PPPM) health care costs were
calculated.
Results: A total of 1,210 patients with NSCLC were included in the analysis. Most
patients (93.6%) had evidence of diagnostic tests beginning 5 to 6 months
prior to diagnosis, and most were diagnosed at an advanced stage (23% Stage
IIIb and 46% Stage IV). The PPPM total health care costs in USD pre- and
postdiagnosis were $2,407±$3,364 (mean±standard deviation) and $16,577±$33,550,
respectively. PPPM total health care costs and utilization after lung cancer
diagnosis were significantly higher among patients diagnosed at Stage IV
disease and lowest among patients diagnosed at Stage I disease ($7,239 Stage I,
$9,484 Stage II, $11,193 Stage IIIa, $17,415 Stage IIIb, and $21,441 Stage IV).
Conclusion: This study showed that most patients experienced long periods of delay
between their first diagnostic test for lung cancer and a definitive diagnosis,
and the majority were diagnosed at advanced stages of disease. Costs associated
with the management of lung cancer increased substantially with higher stages
at diagnosis. Procedures that diagnose lung cancer at earlier stages may allow
for less resource use and costs among patients with lung cancer.
Keywords: biopsy (lung), cost, health care utilization, pulmonary nodule, staging
